Alan JACKSON

En résumé

Entreprises

• Novartis - Laboratory Head

  RUEIL MALMAISON maintenant

• Independent/Free Lance - Full Time Trader

  2009 - maintenant Jan 2009 – Present Time: Full Time Trader.
  Since leaving Novartis in January 2009 I have been trading shares on the UK stock exchanges. I started share trading on a small scale a long time prior to this having noticed that a combination of leverage and market volatility provided the possibility to generate profits. I’m currently enjoying researching companies and markets, making decisions and acting upon them. This work has offered me the opportunity to experience pure decision making and total responsibility for my actions. On a less positve note, the lifestyle is a rather isolated one, and at times I miss the daily interactions inherent in my previous role as lab head in a pharmaceutical company.

• Novartis - Laboratory Head

  RUEIL MALMAISON 1999 - 2009 Laboratory Head (Novartis, Respiratory) Oct 1999-Jan 2009
  Reporting to in vitro/in vivo pharmacology head. Leading multi-disciplinary teams of researchers in the areas of target discovery, model development and early drug discovery programs.
  
  Project Team Leader Epithelial Cell Biology Milestone 2004-Aug 2007
  • delivered state of the art understanding in the areas of goblet cell formation, mucus secretion, regulation of fluid secretion and epithelial integrity providing Novartis with the basic biology expertise to continue to develop a world leading position in these areas. This work identified new mediators, concepts, mechanisms and targets.
  • delivered a validated, novel drugable target regulating goblet cell formation (patented) plus 3 validated backup targets. Accepted as drug discovery project in Dec 2004. Screening completed, multiple chemical scaffolds identified with requisite potency.
  • identified alternative to a generally accepted ‘fundamental’ dogma providing Novartis uninhibited access to a heavily patented area.
  
  Project Team Leader epithelial cell biology 1999-2004
  • appointed by UK research head to lead 5 year ‘milestone’ project to identify epithelial cell biology targets differentiating Novartis from its competitors. Reporting directly to global head of research (Mark Fishman) and his research board bi-annually and to Novartis’ CEO (Dan Vasella) research board annually.
  • Novartis group recognized as pre-eminent industrial mucus hypersecretion group in the world and possesses a platform of models, methods and techniques maximising chances of success in the future.
  • epithelial cell biology recognized by Global Head of Research as fundamentally important to drug/target discovery in respiratory disease in early 2004 and awarded ‘Milestone’ status.
  • first drug discovery project initiated in 2000. 3 additional drug discovery projects derived from these efforts to 2009.
  • set up models, methods and assays permitting Novartis to successfully enter the field of mucus hypersecretion in respiratory disease at a time other companies were leaving this area due to technical difficulties.
  • developed a strong network of academic contacts.
  
  Program Team Leader
  Dec 2003-Dec 2004: Drug Discovery; CNS; smoking cessation. Cross-continent collaborative program to identify antagonists of GPCR ‘X’. Delivered numerous chemical scaffolds including confirmed hits with IC50 < 80nM.
  Jul 2002-Nov 2002: Drug discovery; Respiratory (channel). Delivered literature based target/novel rationale to management. Initiated drug discovery project. Delivered strong 1ry assay + data from core-set indicating likely screening success. Project transferred to another disease area.
  Oct 2001-Nov 2002: Drug discovery; Respiratory (GPCR). Delivered literature based target/Novel rationale to management. Initiated drug discovery project. Delivered 1ry screen. Identified single chemical scaffold with red flag. Schild analysis did not indicate compounds were competitive inhibitors. No ligands available for displacement studies. Terminated project on grounds of risk/feasibility.
  
  1997-2009
  • Played a key role in determining areas of interest for Novartis Respiratory, developing models and methodologies. Delivered routine models of inflammation including. Initiated discussions on development of ‘smoking models’ at a time when general opinion was that this would not be permitted by HO. Novartis was one of two companies granted a 5 year probationary licence for smoking models by the Home Office.
  • Member of a number of strategy teams for respiratory drug discovery and also for smoking cessation (CNS).

• National Heart & Lung Institute Dept of Thoracic Medicine, London UK. - Post Doctoral Research Fellow

  1992 - 1997 1992-1997 Post-Doctoral Research Fellow, Host Defence Unit. Wellcome project grant M/90/299.
  • Characterisation of the host-bacterial interactions during colonisation of human respiratory mucosa by non-typeable Haemophilus influenzae, Haemophilus influenzae type b, Neisseria meningitides & Streptococcus pneumoniae. Delivered organ culture model of human respiratory mucosa & 10 peer reviewed papers.

• Dept Biology & Pre-clinical Medicine, St Andrews University, UK - Post Doctoral Research Fellow

  1989 - 1992 Wellcome project grant.
  Project aim was to determine whether the pro-phenoloxidase system (a central element of arthropod non-adaptive host defence) was present in the proto-chordates (most primitive known vertebrate ancestors). Identified ProPO cascade in Ciona intestinalis. Identified 2 stimuli capable of activating it & 2 compounds capable of inhibiting its activation. Delivered 2 peer reviewed publications.

Formations

Réseau

• Daphné MARTIN

• Delphine NICOLAS

• Laetitia MARTIN

• Pierdet GAËLLE

• Sebastien LARUE